Onivyde for the therapy of multiple solid tumors

Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticance...

Descripción completa

Detalles Bibliográficos
Autor principal: Zhang, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881920/
https://www.ncbi.nlm.nih.gov/pubmed/27284250
http://dx.doi.org/10.2147/OTT.S105587
_version_ 1782434040357322752
author Zhang, Haijun
author_facet Zhang, Haijun
author_sort Zhang, Haijun
collection PubMed
description Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors.
format Online
Article
Text
id pubmed-4881920
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48819202016-06-09 Onivyde for the therapy of multiple solid tumors Zhang, Haijun Onco Targets Ther Review Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents, which has revolutionized tumor therapy. Onivyde, also known as MM-398 or PEP02, is a nanoliposomal formulation of irinotecan which has demonstrated encouraging anticancer activity across a broad range of malignancies, including pancreatic cancer, esophago-gastric cancer, and colorectal cancer. This up-to-date review not only focuses on the structure, pharmacokinetics, and pharmacogenetics of Onivyde but also summarizes clinical trials and recommends Onivyde for patients with advanced solid tumors. Dove Medical Press 2016-05-20 /pmc/articles/PMC4881920/ /pubmed/27284250 http://dx.doi.org/10.2147/OTT.S105587 Text en © 2016 Zhang. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Zhang, Haijun
Onivyde for the therapy of multiple solid tumors
title Onivyde for the therapy of multiple solid tumors
title_full Onivyde for the therapy of multiple solid tumors
title_fullStr Onivyde for the therapy of multiple solid tumors
title_full_unstemmed Onivyde for the therapy of multiple solid tumors
title_short Onivyde for the therapy of multiple solid tumors
title_sort onivyde for the therapy of multiple solid tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881920/
https://www.ncbi.nlm.nih.gov/pubmed/27284250
http://dx.doi.org/10.2147/OTT.S105587
work_keys_str_mv AT zhanghaijun onivydeforthetherapyofmultiplesolidtumors

Ejemplares similares